Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TYMS | P04818 | 6/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | S100A4 | P26447 | 1/20 | 0.51 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30067536 | 1.00 | ALDH1A1 (0.68) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL16230011 | 0.87 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL975376 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL29383750 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Acenaphthene SCHEMBL3416108 | 0.77 | TSHR (0.57) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Acenaphthene SCHEMBL9017 | 0.77 | TSHR (0.57) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Acenaphthene SCHEMBL1162573 | 0.77 | TSHR (0.57) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Acenaphthene SCHEMBL29386207 | 0.77 | TSHR (0.57) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Acenaphthene SCHEMBL598252 | 0.77 | TSHR (0.57) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Acenaphthene SCHEMBL28028969 | 0.77 | TSHR (0.57) | ALDH1A1KDM4EHPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | claimed |
| JP-3119718-A | — | — | None | — | — | JP | disclosed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| US-11913884-B2 | Visible light-activated dyes and methods of use thereof | WILLIAM MARSH RICE UNIVERSITY (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11768434-B2 | Polymer having a structure of polyamide, polyamide-imide, or polyimide, photosensitive resin composition, patterning process, photosensitive dry film, and protective film for electric and electronic parts | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-26 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023010119-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-0281381-B1 | ELECTROLUMINESCENT DEVICE WITH MODIFIED THIN FILM LUMINESCENT ZONE | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1992-07-15 | — | — | EP | disclosed |
| JP-H03119718-A | FORMATION OF RESIST PATTERN | OKI ELECTRIC IND CO LTD | 1991-05-22 | — | — | JP | disclosed |
| US-4933948-A | Inclusion compound of cyclodextrin and fluorescent dye | EASTMAN KODAK COMPANY (US) | 1990-06-12 | — | — | US | disclosed |
| US-4927927-A | Fluorescent dyes and biological and analytical uses thereof | EASTMAN KODAK COMPANY (US) | 1990-05-22 | — | — | US | disclosed |
| EP-0349265-A2 | Electroluminescent devices | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-01-03 | — | — | EP | disclosed |
| US-4812393-A | ANALYTICAL DETERMINATION OF MICROORGANISMS | EASTMAN KODAK COMPANY (US) | 1989-03-14 | — | — | US | disclosed |
| EP-0281381-A2 | Electroluminescent device with modified thin film luminescent zone | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1988-09-07 | — | — | EP | disclosed |
| US-4769292-A | Electroluminescent device with modified thin film luminescent zone | EASTMAN KODAK COMPANY (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0231127-A2 | Composition, element and method using polymeric mordants to increase the intensity of rigid fluorescent dyes | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1987-08-05 | — | — | EP | disclosed |
| EP-0231126-A2 | Fluorescent dyes and biological and analytical uses thereof | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1987-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | ALDH1A1 379/4885KDM4E 714/4885HPGD 958/4885 |
| US-11913884-B2 | Visible light-activated dyes and methods of use thereof | HCCS, CLTB, ALDH1A2 | ALDH1A1 311/4885KDM4E 3264/4885HPGD 2058/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | ALDH1A1 3441/4885KDM4E 4039/4885HPGD 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.